National not-for-profit organisation Omico is hosting a webinar later this month to help people learn more about comprehensive genomic profiling, precision oncologythe study, diagnosis and treatment of cancer and how they could benefit.
Omico is speeding up access to precision oncology through an initiative called PrOSPeCT (Precision Oncology Screeningtesting for cancer or conditions that can lead to cancer before symptoms appear, also known as cancer screening Platform Enabling Clinical Trialsresearch studies performed to test new treatments, tests or procedures and evaluate their effectiveness on various diseases).
PrOSPeCT is the largest genomics cancera disease where abnormal cells split without control and spread to other nearby body tissue and/or organs initiative in Australia, aiming to profile 23,000 people who have advancedat a late stage, far along or incurable cancers.
The results of genomic profiling could help match patients with precision treatments that specifically target the features of their cancer.
A precision approach can provide more effective treatment or reduced side effects compared to traditional cancer treatments.
Omico’s webinar on Thursday 18 July will give people the chance to hear for themselves from the Omico team, including Chief Science and Strategy Officer Professor David Thomas, Head of Cohorts A/Professor Mandy Ballinger, and Beth Ivemy, who was diagnosed with bile duct cancer two years ago and has experienced comprehensive genomic profiling herself.
Attendees will:
- Learn more about precision oncology and comprehensive genomic profiling
- Find out about who it’s for and what it can offer
- See what’s involved in taking part
- Hear from someone who has experienced comprehensive genomic profiling first-hand
- Have the opportunity to ask questions.